Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
Voyager Therapeutics announced eight presentations at ASGCT 2026 including a late-breaking oral presentation highlighting the safety and pharmacology of VY1706, its IV-delivered tau-silencing gene therapy targeting Alzheimer's disease. The company plans to submit an IND in Q2 2026 and initiate first-in-human dosing in the second half of 2026. Addit…